Sotera Health Company provides sterilization, and lab testing and advisory services to the medical device, pharmaceutical, and food products industries in the Americas, Europe and Asia. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.
IPO Year: 2020
Exchange: NASDAQ
Website: soterahealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/21/2024 | $13.00 | Neutral | Piper Sandler |
| 4/3/2024 | $18.00 → $16.00 | Neutral → Buy | Citigroup |
| 3/25/2024 | $15.00 → $15.50 | Hold → Buy | Jefferies |
| 2/6/2024 | Sector Weight | KeyBanc Capital Markets | |
| 6/26/2023 | $24.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 1/23/2023 | $6.00 → $18.00 | Underweight → Neutral | JP Morgan |
| 1/11/2023 | $6.00 → $22.00 | Underweight → Overweight | Barclays |
| 1/11/2023 | $25.00 | Peer Perform → Outperform | Wolfe Research |
| 11/15/2022 | $6.00 | Equal Weight → Underweight | Barclays |
| 10/5/2022 | $25.00 → $9.00 | Buy → Neutral | Citigroup |
8-K - Sotera Health Co (0001822479) (Filer)
10-Q - Sotera Health Co (0001822479) (Filer)
8-K - Sotera Health Co (0001822479) (Filer)
8-K - Sotera Health Co (0001822479) (Filer)
424B7 - Sotera Health Co (0001822479) (Filer)
424B7 - Sotera Health Co (0001822479) (Filer)
10-Q - Sotera Health Co (0001822479) (Filer)
8-K - Sotera Health Co (0001822479) (Filer)
8-K - Sotera Health Co (0001822479) (Filer)
SD - Sotera Health Co (0001822479) (Filer)
4 - Sotera Health Co (0001822479) (Issuer)
4 - Sotera Health Co (0001822479) (Issuer)
4 - Sotera Health Co (0001822479) (Issuer)
4 - Sotera Health Co (0001822479) (Issuer)
4 - Sotera Health Co (0001822479) (Issuer)
4 - Sotera Health Co (0001822479) (Issuer)
3 - Sotera Health Co (0001822479) (Issuer)
4 - Sotera Health Co (0001822479) (Issuer)
4 - Sotera Health Co (0001822479) (Issuer)
4 - Sotera Health Co (0001822479) (Issuer)
SC 13G/A - Sotera Health Co (0001822479) (Subject)
SC 13G/A - Sotera Health Co (0001822479) (Subject)
SC 13G/A - Sotera Health Co (0001822479) (Subject)
SC 13G/A - Sotera Health Co (0001822479) (Subject)
SC 13G - Sotera Health Co (0001822479) (Subject)
SC 13G/A - Sotera Health Co (0001822479) (Subject)
SC 13G - Sotera Health Co (0001822479) (Subject)
SC 13G - Sotera Health Co (0001822479) (Subject)
CLEVELAND, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, will hold an Investor Day in New York City where Sotera Health's management team will discuss the Company's strategic positioning and outline future growth plans. Management will take questions from a live audience during two question-and-answer sessions. "The management team is looking forward to the Company's inaugural Investor Day since going public in 2020," said Michael J. Petras, Jr., Chair and CEO. "During the past four years, we have achieved top- and bo
Q3 2024 net revenues of $285 million increased 8.5%, compared to Q3 2023Q3 2024 net income of $17 million or $0.06 per diluted share, compared to net loss of $14 million or $0.05 per diluted share in Q3 2023 Q3 2024 Adjusted EBITDA(1) of $146 million increased 9.0%, compared to Q3 2023Q3 2024 Adjusted EPS(1) of $0.17 increased $0.01 per diluted share, compared to Q3 2023Reaffirming 2024 Net Revenue and Adjusted EBITDA outlook ranges CLEVELAND, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry,
CLEVELAND, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third-quarter ended September 30, 2024 before the market opens on Tuesday, November 5, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from other locations.
CLEVELAND, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC) (the "Company") today announced the launch of a secondary offering (the "Offering") of 25,000,000 shares of its common stock, par value $0.01 per share. All 25,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC ("Warburg Pincus") and GTCR LLC ("GTCR") as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. It is expected that, as a result of the Offering, the Company's sponsors (affiliates of Warburg Pincus and GTCR) will cease to own a majority of the Company's outstanding common stock, which will affect certain sponsor rights and
Q2 2024 net revenues of $277 million increased 8%, compared to Q2 2023Q2 2024 net income of $9 million or $0.03 per diluted share, compared to net income of $24 million or $0.08 per diluted share in Q2 2023Q2 2024 Adjusted EBITDA(1) of $137 million increased 7%, compared to Q2 2023Q2 2024 Adjusted EPS(1) of $0.19 declined $0.01 per diluted share, compared to Adjusted EPS of $0.20 in Q2 2023Successfully refinanced debt structure, extending debt maturities to 2031Reaffirming 2024 outlook CLEVELAND, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab test
CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ
CLEVELAND, July 22, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the second-quarter ended June 30, 2024 before the market opens on Monday, August 5, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from other locations. A live
CLEVELAND, May 30, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced that its direct subsidiary has successfully closed a new senior secured Term Loan B facility in an aggregate principal amount of $1.51 billion (the "TLB") as well as an issuance of senior secured notes in an aggregate principal amount of $750.0 million (the "Notes") (collectively, the "Financings"), both of which mature in 2031. The Company used the net proceeds from the Financings, along with cash on hand, to refin
Q1 2024 net revenues increased 12.5% to $248 million, compared to Q1 2023Q1 2024 net income of $6 million or $0.02 per diluted share, compared to net income of $3 million or $0.01 per diluted share in Q1 2023Q1 2024 Adjusted EBITDA(1) increased 13.7% to $112 million, compared to Q1 2023Q1 2024 Adjusted EPS(1) of $0.13 compared to Adjusted EPS of $0.13 in Q1 2023Company reaffirms 2024 outlook CLEVELAND, May 02, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the
CLEVELAND, April 11, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the first-quarter ended March 31, 2024 before the market opens on Thursday, May 2, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from other locations. A live
CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ
CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal
WESTPORT, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE:CODI) ("CODI" or the "Company"), an owner of leading middle market businesses, today announced the appointment of Kurt Roth as Partner and Head of Healthcare for Compass Group Management LLC. In this role, Roth will work with the organization's senior investment professionals to launch CODI's new healthcare vertical. "Last December, we embarked on a journey to launch our third industry vertical," said Elias Sabo, CEO of Compass Diversified. "We chose healthcare as we believe it has multiple attractive, high-growth sectors with strong barriers to entry and advantageous demographic trends. Finding the right perso
CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Jon Giacomin to the Company's Board of Directors, effective May 7, 2021. The Company also announced that Wayne Mackie resigned as a member of the Company's Board of Directors effective May 7, 2021. Mr. Mackie's resignation was not due to any disagreement with the Company on any matter relating to its operations, policies or practices. "Jon is a proven leader who brings signifi
Q3 2024 net revenues of $285 million increased 8.5%, compared to Q3 2023Q3 2024 net income of $17 million or $0.06 per diluted share, compared to net loss of $14 million or $0.05 per diluted share in Q3 2023 Q3 2024 Adjusted EBITDA(1) of $146 million increased 9.0%, compared to Q3 2023Q3 2024 Adjusted EPS(1) of $0.17 increased $0.01 per diluted share, compared to Q3 2023Reaffirming 2024 Net Revenue and Adjusted EBITDA outlook ranges CLEVELAND, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry,
CLEVELAND, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third-quarter ended September 30, 2024 before the market opens on Tuesday, November 5, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from other locations.
Q2 2024 net revenues of $277 million increased 8%, compared to Q2 2023Q2 2024 net income of $9 million or $0.03 per diluted share, compared to net income of $24 million or $0.08 per diluted share in Q2 2023Q2 2024 Adjusted EBITDA(1) of $137 million increased 7%, compared to Q2 2023Q2 2024 Adjusted EPS(1) of $0.19 declined $0.01 per diluted share, compared to Adjusted EPS of $0.20 in Q2 2023Successfully refinanced debt structure, extending debt maturities to 2031Reaffirming 2024 outlook CLEVELAND, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab test
CLEVELAND, July 22, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the second-quarter ended June 30, 2024 before the market opens on Monday, August 5, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from other locations. A live
Q1 2024 net revenues increased 12.5% to $248 million, compared to Q1 2023Q1 2024 net income of $6 million or $0.02 per diluted share, compared to net income of $3 million or $0.01 per diluted share in Q1 2023Q1 2024 Adjusted EBITDA(1) increased 13.7% to $112 million, compared to Q1 2023Q1 2024 Adjusted EPS(1) of $0.13 compared to Adjusted EPS of $0.13 in Q1 2023Company reaffirms 2024 outlook CLEVELAND, May 02, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the
CLEVELAND, April 11, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the first-quarter ended March 31, 2024 before the market opens on Thursday, May 2, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from other locations. A live
2023 net revenues increased 4.5% to $1.05 billion, compared to 20222023 net income of $51 million or $0.18 per diluted share2023 Adjusted EBITDA(1) increased 4.3% to $528 million2023 Adjusted EPS(1) decreased $0.15 to $0.81 per diluted shareFull-year 2024 outlook of 4.0% - 6.0% growth for Net Revenues and Adjusted EBITDA CLEVELAND, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the fourth-quarter and full-year 2023 and its initial 2024 outlook. For th
CLEVELAND, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2023 before the market opens on Tuesday, February 27, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from o
Q3 2023 net revenues of $263 million increased 6%, compared to Q3 2022Q3 2023 net loss of $14 million or $0.05 per diluted share, compared to net income of $25 million or $0.09 per diluted share in Q3 2022 Q3 2023 Adjusted EBITDA of $134 million increased 7%, compared to Q3 2022Q3 2023 Adjusted EPS of $0.21 decreased $0.02 per diluted share, compared to Q3 2022 driven by higher interest expenseCompany reaffirms 2023 outlook, anticipates results at the lower end of the range CLEVELAND, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advi
CLEVELAND, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third-quarter ended September 30, 2023 before the market opens on Wednesday, November 1, 2023. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412- 317-0709 if dialing-in from oth
Piper Sandler initiated coverage of Sotera Health with a rating of Neutral and set a new price target of $13.00
Citigroup upgraded Sotera Health from Neutral to Buy and set a new price target of $16.00 from $18.00 previously
Jefferies upgraded Sotera Health from Hold to Buy and set a new price target of $15.50 from $15.00 previously
KeyBanc Capital Markets resumed coverage of Sotera Health with a rating of Sector Weight
KeyBanc Capital Markets upgraded Sotera Health from Sector Weight to Overweight and set a new price target of $24.00
JP Morgan upgraded Sotera Health from Underweight to Neutral and set a new price target of $18.00 from $6.00 previously
Barclays upgraded Sotera Health from Underweight to Overweight and set a new price target of $22.00 from $6.00 previously
Wolfe Research upgraded Sotera Health from Peer Perform to Outperform and set a new price target of $25.00
Barclays downgraded Sotera Health from Equal Weight to Underweight and set a new price target of $6.00
Citigroup downgraded Sotera Health from Buy to Neutral and set a new price target of $9.00 from $25.00 previously
Ratings for Sotera Health (NASDAQ:SHC) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 4 1 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 2 1 0 0 0 3M Ago 0 3 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $16.79, with a high estimate of $20.00 and a low estimate of $13.00. A decline of 2.67% from the prior aver
Piper Sandler analyst Jason Bednar initiates coverage on Sotera Health (NASDAQ:SHC) with a Neutral rating and announces Price Target of $13.
Sotera Health (NASDAQ:SHC) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.12 by 8.33 percent. This is unchanged from the same period last year. The company reported quarterly sales of $248.176 million which beat the analyst consensus estimate of $244.350 million by 1.57 percent. This is a 12.51 percent increase over sales of $220.590 million the same period last year.
Barclays analyst Luke Sergott maintains Sotera Health (NASDAQ:SHC) with a Overweight and lowers the price target from $19 to $14.
6 analysts have shared their evaluations of Sotera Health (NASDAQ:SHC) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 4 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 2 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 1 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $17.92, a high estimate of $20.00, and a low estimate of $15.50. This upward trend is apparent, with the cu
Citigroup analyst Patrick Donnelly upgrades Sotera Health (NASDAQ:SHC) from Neutral to Buy and lowers the price target from $18 to $16.
Jefferies analyst David Windley upgrades Sotera Health (NASDAQ:SHC) from Hold to Buy and raises the price target from $15 to $15.5.
Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and board changes. Lifecore Biomedical shares dipped 31.7% to $4.91 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers ETAO International Co., Ltd. (NASDAQ:ETAO) shares shot up 111.5% to $0.3025. The company announced a reverse stock split. XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) gained 74.3% to $1.7950 after the company announced plans to acquire The Social Proxy. TruGolf Holdings, Inc. (NASDAQ:TRUG) shares climbed 56% to $1.7938 after the company an